Know Cancer

or
forgot password

A Pilot Study Utilizing Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers


Phase 0
18 Years
N/A
Not Enrolling
Both
Refractory Cancer

Thank you

Trial Information

A Pilot Study Utilizing Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers


Inclusion Criteria:



- Metastatic cancer which has progressed on 2 prior chemotherapeutic, hormonal or
biological regimens for advanced disease.

- Be defined as refractory to the last line of therapy

- Have documentation of the best clinical response to the treatment regimen immediately
prior to entering this study

Exclusion Criteria:

- Patients with symptomatic CNS metastasis

- Any previous history of another malignancy within 5 years of study entry

- Uncontrolled intercurrent illness

- Known HIV, HBV, HCV infection

- Pregnant or breast-feeding

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To compare progression-free survival using a treatment regimen selected by molecular profiling with progression-free survival for the most recent regimen the patient has progressed on.

Outcome Time Frame:

Every 8 weeks disease assessments are performed

Safety Issue:

No

Principal Investigator

Daniel D Von Hoff, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

TGen Clinical Research Services at Scottsdale Healthcare

Authority:

United States: Institutional Review Board

Study ID:

SCRI-CA-001

NCT ID:

NCT00530192

Start Date:

September 2006

Completion Date:

March 2009

Related Keywords:

  • Refractory Cancer
  • Refractory Cancer
  • Molecular Profile

Name

Location
Tyler Cancer Center Tyler, Texas  75702
Mayo Clinic Scottsdale, Arizona  
Cancer Center of the Carolinas Greenville, South Carolina  29615
Central indiana Cancer Center Indianapolis, Indiana  46227
Tower Oncology Beverly Hills, California  90211
Oncology Specialties Huntsville, Alabama  35805
TGen Clinical Research Services Scottsdale, Arizona  85258
Louis Warschaw Prostate Cancer Center at Cedars Sinai Medical Center Los Angeles, California  90048
South Texas Oncology Hematology San Antonio, Texas  78229